News for Inozyme Pharma, Inc. (INZY)

On June 30, 2025, BlackRock, Inc. (Trades, Portfolio) executed a notable transaction involving Inozyme Pharma Inc (INZY), reducing its holdings by 1,081,439 sha

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On July 1, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced the finalization of its acquisition of Inozyme Pharma, Inc. The deal is valued at $270 million, and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has paid $4.00 per share in cash for all […]

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. ( INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the ”œA

On May 16, 2025, Beryl Capital Management LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 6,321,584 shares of Inozyme Pharma Inc (INZY) a

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of

PR NewswireNEW YORK, May 22, 2025 NEW YORK, May 22, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following comp

PR NewswireNEW YORK, May 19, 2025 NEW YORK , May 19, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following com

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of

On May 16, 2025, Inozyme Pharma (INZY) received a notable analyst action from Wells Fargo. Tiago Fauth, an analyst at the firm, downgraded the stock rating from

Weekly Market Recap Stocks had a winning week with the S&P 500 and Dow Jones Industrial Average turning positive for the year, up by 1.3% and 0.3% respecti

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Friday. The Dow traded up 0.59% to 42,570.89 while the NAS...

U.S. stocks traded slightly higher this morning, with the Nasdaq Composite gaining around 0.2% on Friday. Following the market opening Friday, the Dow traded u...

PR NewswireSAN RAFAEL, Calif. and BOSTON, May 16, 2025 Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Thera

On December 31, 2024, Eventide Asset Management, LLC executed a significant transaction involving Inozyme Pharma Inc (NASDAQ: INZY). The firm reduced its holdin

- Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease's serious cardiovascular and musculoskele

**media[581370]**

- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including

**media[561890]**

**media[548596]**